NYSE:BIOABioamber Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bioamber Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume15.51 million shsAverage Volume2.97 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Bioamber. Previous Next 2.9 Community Rank Outperform VotesBioamber has received 288 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioamber has received 213 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioamber has received 57.49% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bioamber and other stocks. Vote “Outperform” if you believe BIOA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BIOA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioamber does not currently pay a dividend.Dividend GrowthBioamber does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bioamber insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.33% of the stock of Bioamber is held by insiders.Percentage Held by InstitutionsOnly 28.70% of the stock of Bioamber is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.58 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNYSE:BIOA Previous Symbol CUSIPN/A CIK1534287 Webwww.bio-amber.com Phone+1-612-7474423Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive BIOA News and Ratings via Email Sign-up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Bioamber (NYSE:BIOA) Frequently Asked Questions How were Bioamber's earnings last quarter? Bioamber Inc (NYSE:BIOA) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.02. The biotechnology company earned $2.50 million during the quarter, compared to analysts' expectations of $2.37 million. View Bioamber's earnings history. Has Bioamber been receiving favorable news coverage? News articles about BIOA stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bioamber earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutBioamber. What other stocks do shareholders of Bioamber own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioamber investors own include ProQR Therapeutics (PRQR), Flexion Therapeutics (FLXN), Rite Aid (RAD), CytRx (CYTR), IntelliPharmaCeutics Intl (IPCIF), Biopharmx (BPMX), Eyepoint Pharmaceuticals (EYPT), Moneygram International (MGI), AbbVie (ABBV) and Aurinia Pharmaceuticals (AUPH). Who are Bioamber's key executives? Bioamber's management team includes the following people: Raymond J. Land, Chairman of the Board (Age 72)Richard P. Eno, Chief Financial Officer, DirectorMario Settino, Chief Financial OfficerMichael A. Hartmann, Executive Vice President (Age 48)James Millis, Chief Technology Officer (Age 59)Robert Frost, DirectorKurt W. Briner, Independent Director (Age 70)Heinz Haller, Independent Director (Age 62)Ellen B. Richstone, Independent Director (Age 65)Kenneth W Wall, Independent Director (Age 66) What is Bioamber's stock symbol? Bioamber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA." What is Bioamber's official website? The official website for Bioamber is www.bio-amber.com. How can I contact Bioamber? Bioamber's mailing address is 3850 Annapolis Ln N Ste 180, PLYMOUTH, MN 55447-5476, United States. The biotechnology company can be reached via phone at +1-612-7474423 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
